First patient treated in trial of ReNeuron’s retinitis pigmentosa cell therapy
ReNeuron has demonstrated that its Human Retinal Progenitor Cells (hRPCs) improve visual acuity in preclinical models of retinal degeneration...
List view / Grid view
News
FDA grants priority review to Roche’s atezolizumab in urothelial carcinoma
15 March 2016 | By Victoria White
The priority review is based on results of the IMvigor 210 study that evaluated the safety and efficacy of atezolizumab in people with locally advanced or metastatic urothelial carcinoma, regardless of PD-L1 expression.
First real-world evidence comparing an SGLT2 inhibitor with DPP-4 inhibitors
15 March 2016 | By Victoria White
A real-world study showed use of Invokana (canagliflozin) is associated with significantly greater improvements in blood glucose control compared to DPP-4 inhibitors...
Forecasting in dynamic Oncology Markets
14 March 2016 | By Black Swan Analysis
Two big things struck me as interesting during an Innovations in Oncology Conference in Edinburgh this month...
Wickham Labs to Exhibit at Med-Tech Innovation Expo 2016
14 March 2016 | By Wickham Laboratories Ltd
Wickham Laboratories Ltd will be on Stand 12 at the upcoming Med-Tech Innovation Expo at the Ricoh Arena in Coventry, April 20-21...
Wickham Labs to Exhibit at Making Pharmaceuticals 2016
14 March 2016 | By Wickham Laboratories Ltd
Wickham Laboratories Ltd will exhibit on Stand 307 at Making Pharmaceuticals, April 26-27...
Abiraterone acetate plus prednisone shows survival benefit in early mCRPC
14 March 2016 | By Victoria White
In a study, abiraterone acetate plus prednisone provided an 11.8 months overall survival benefit compared to an active control of placebo plus prednisone...
GW announces positive results for Epidiolex in Dravet syndrome
14 March 2016 | By Victoria White
Epidiolex achieved the primary endpoint of a significant reduction in convulsive seizures assessed over the entire treatment period compared with placebo...
EMA to review Gilead’s Zydelig over safety concerns
14 March 2016 | By Victoria White
The European Medicines Agency's review follows concerns over serious adverse events in ongoing clinical trials of Zydelig (idelalisib)...
Lundbeck starts Lu AF35700 Phase III programme in treatment-resistant schizophrenia
14 March 2016 | By Victoria White
The Phase III programme will consist of two pivotal trials. Two doses of Lu AF35700 will be tested in patients with treatment resistant schizophrenia...
FDA approves sNDA for Xalkori in ROS1-positive NSCLC
14 March 2016 | By Victoria White
The approval is based on a Phase I study that included 50 patients with ROS1-positive metastatic NSCLC treated with 250 mg of Pfizer's Xalkori (crizotinib) orally twice daily...
Stay ahead in Biopharma
The Thermo Fisher Scientific™ global bio/pharma tour is an opportunity to collaborate and network directly with experts in technology innovation...
Lapatinib and trastuzumab shrinks HER2+ breast cancers within 11 days
11 March 2016 | By Victoria White
A trial has shown that lapatinib plus trastuzumab before surgery shrinks and may even destroy tumours in women with HER2+ breast cancer within 11 days. The EPHOS B trial studied 257 women with HER2 positive breast cancer in the short gap between initial diagnosis and surgery to remove their tumours.…
sarilumab demonstrates superiority to adalimumab in rheumatoid arthritis
11 March 2016 | By Victoria White
A Phase III study demonstrated that sarilumab was superior to adalimumab in improving signs and symptoms in patients with active RA...
Teva supports IVF Worldwide to improve knowledge of fertility preservation protocols
10 March 2016 | By Victoria White
Teva is to support IVF-Worldwide with a research grant to improve knowledge of fertility preservation protocols for women diagnosed with cancer...
